AngioDynamics Stock Price, Forecast & Analysis (NASDAQ:ANGO)

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) released its earnings results on Thursday, October, 3rd. The medical instruments supplier reported $0.08 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.04 by $0.04. The medical instruments supplier earned $66 million during the quarter, compared to the consensus estimate of $67.74 million. AngioDynamics had a net margin of 17.79% and a return on equity of 4.89%. The company's revenue was up 3.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.16 EPS. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Friday, January 3rd 2020. View Earnings Estimates for AngioDynamics.

AngioDynamics updated its FY20 earnings guidance on Thursday, October, 3rd. The company provided earnings per share guidance of $0.10-0.15 for the period, compared to the Thomson Reuters consensus estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $281.89 million.

2 analysts have issued 1-year price objectives for AngioDynamics' stock. Their forecasts range from $21.00 to $23.00. On average, they anticipate AngioDynamics' stock price to reach $22.00 in the next year. This suggests a possible upside of 42.5% from the stock's current price. View Analyst Price Targets for AngioDynamics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AngioDynamics.

News headlines about ANGO stock have been trending very positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AngioDynamics earned a media sentiment score of 3.3 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for AngioDynamics.

AngioDynamics saw a decline in short interest in October. As of October 31st, there was short interest totalling 748,500 shares, a decline of 7.9% from the September 30th total of 812,500 shares. Based on an average trading volume of 267,200 shares, the short-interest ratio is currently 2.8 days. Currently, 2.0% of the shares of the stock are sold short. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Oasis Petroleum (OAS), Intel (INTC), General Electric (GE), Mattel (MAT), Chesapeake Energy (CHK), Centurylink (CTL), Hanesbrands (HBI), Baidu (BIDU), Cerner (CERN) and FireEye (FEYE).

AngioDynamics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Tributary Capital Management LLC (1.80%), Fenimore Asset Management Inc. (1.52%), Systematic Financial Management LP (1.09%), Foundry Partners LLC (0.65%), State of New Jersey Common Pension Fund D (0.40%) and Rhumbline Advisers (0.32%). Company insiders that own AngioDynamics stock include James C Clemmer, Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Foundry Partners LLC, Keybank National Association OH, Municipal Employees Retirement System of Michigan, Brinker Capital Inc., Strs Ohio, First National Bank of Omaha and Hancock Whitney Corp. View Insider Buying and Selling for AngioDynamics.

ANGO stock was acquired by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Mackay Shields LLC, Assenagon Asset Management S.A., Boston Advisors LLC, Systematic Financial Management LP, Tibra Equities Europe Ltd, Meeder Asset Management Inc. and State of Alaska Department of Revenue. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $15.44.

AngioDynamics has a market capitalization of $580.85 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]